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ORIGINAL INVESTIGATION
Effect of alirocumab on individuals 
with type 2 diabetes, high triglycerides, and low 
high-density lipoprotein cholesterol
Helen M. Colhoun1*, Lawrence A. Leiter2, Dirk Müller‑Wieland3, Bertrand Cariou4, Kausik K. Ray5, 
Francisco J. Tinahones6, Catherine Domenger7, Alexia Letierce8, Marc Israel9, Rita Samuel9 
and Stefano Del Prato10
Abstract 
Background: Mixed dyslipidemia [elevated non‑high‑density lipoprotein cholesterol (non‑HDL‑C) and triglycerides 
(TGs), and decreased HDL‑C] is common in type 2 diabetes mellitus (T2DM) and is associated with increased cardio‑
vascular risk. Non‑HDL‑C and apolipoprotein B (ApoB) are the preferred therapeutic targets for mixed dyslipidemia. 
Alirocumab is a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9) that effectively reduces 
low‑density lipoprotein cholesterol (LDL‑C), non‑HDL‑C, ApoB, and lipoprotein(a) (Lp[a]), and is well‑tolerated in indi‑
viduals with T2DM.
Methods: The previously reported open‑label ODYSSEY DM‑DYSLIPIDEMIA trial data demonstrated the effects of 
alirocumab on individuals with non‐HDL‑C ≥ 100 mg/dL and TGs ≥ 150 and < 500 mg/dL receiving stable maximally 
tolerated statin (n = 413). This post hoc subgroup analysis of the primary trial investigated the effects of alirocumab 
[75 mg every 2 weeks (Q2W) with possible increase to 150 mg Q2W at Week 12] versus usual care [ezetimibe, fenofi‑
brate, or no additional lipid‑lowering therapy (LLT)] on non‑HDL‑C and other lipids in individuals with T2DM and 
baseline TGs ≥ 200 mg/dL and HDL‑C < 40 mg/dL (men) or < 50 mg/dL (women).
Results: Alirocumab significantly reduced non‑HDL‑C [LS mean difference (standard error (SE)), − 35.0% (3.9)], ApoB 
[LS mean difference (SE), − 34.7% (3.6)], LDL‑C [LS mean difference (SE), − 47.3% (5.2)], LDL particle number [LS mean 
difference (SE), − 40.8% (4.1)], and Lp(a) [LS mean difference (SE), − 29.9% (5.4)] versus usual care from baseline to 
Week 24 (all P < 0.0001). Results were similar for alirocumab versus usual care. TG reductions were similar between 
alirocumab and usual care (no significant difference), but greater with fenofibrate versus alirocumab (P = 0.3371). 
Overall, alirocumab significantly increased HDL‑C versus usual care [LS mean difference (SE), 7.9% (3.6); P < 0.05], 
although differences with alirocumab versus ezetimibe or fenofibrate were non‑significant. Most individuals receiving 
alirocumab achieved ApoB < 80 mg/dL (67.9%) and non‑HDL‑C < 100 mg/dL (60.9%). Adverse event frequency was 
similar between alirocumab (67.2%) and usual care (70.7%). Additionally, no clinically relevant effect of alirocumab on 
change in glycemic parameters or use of antihyperglycemic agents was observed.
Conclusions: Alirocumab is an effective therapeutic option for individuals with T2DM, TGs ≥ 200 mg/dL, and 
HDL‑C < 40 mg/dL (men) or < 50 mg/dL (women). Atherogenic lipid (ApoB and non‑HDL) reductions were greater 
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Background
Individuals with type 2 diabetes mellitus (T2DM) are at 
increased risk of atherosclerotic cardiovascular disease 
(ASCVD) [1]. Mixed dyslipidemia, i.e. elevated plasma 
triglycerides (TGs), TG-rich lipoprotein (TRL) and TRL 
cholesterol (TRL-C) levels and decreased levels of high-
density lipoprotein cholesterol (HDL-C) [2], is a major 
contributor to ASCVD risk in individuals with diabetes 
[3, 4]. Individuals with mixed dyslipidemia may also have 
an elevated number of small, dense low-density lipopro-
tein (LDL) particles [2, 5], as reflected by higher levels of 
ApoB-100 (ApoB); however, these individuals may not 
necessarily have elevated LDL cholesterol (LDL-C) levels 
[6].
ApoB-containing lipoproteins have been demonstrated 
to be directly associated with the risk of coronary heart 
disease [7], as indicated by the reduction in cardiovas-
cular risk associated with statin therapy, proportional 
with the reduction in ApoB [8]. In addition, when LDL-C 
and ApoB are discordant, as commonly occurs in insu-
lin-resistant states [9], non-HDL-C and ApoB are con-
sidered to be stronger predictors of cardiovascular risk 
than LDL-C [2, 10, 11]. TGs are not a specific therapeutic 
target in cardiovascular disease; however, when TGs are 
200–499 mg/dL, the primary targets of lipid therapy are 
non-HDL-C and LDL-C [2]. The National Lipid Asso-
ciation recommends non-HDL-C targets of < 130  mg/
dL for individuals at high ASCVD risk and < 100  mg/
dL for those at very-high ASCVD risk, and ApoB tar-
gets of < 90 mg/dL for primary prevention, and < 80 mg/
dL for those with very-high cardiovascular risk [2]. The 
American Association of Clinical Endocrinologists rec-
ommends targets of < 100  mg/dL for non-HDL-C and 
< 80 mg/dL for ApoB in individuals at very-high cardio-
vascular risk, and targets of < 80 mg/dL for non-HDL-C 
and < 70 mg/dL for ApoB for individuals at extreme risk 
[12].
Alirocumab is a monoclonal antibody that binds to 
circulating proprotein convertase subtilisin/kexin type 
9 (PCSK9), which was previously investigated in indi-
viduals with mixed dyslipidemia in the ODYSSEY DM-
DYSLIPIDEMIA trial [13, 14]. This trial was a Phase 3, 
randomized, open-label, parallel group, multinational 
study (NCT02642159) that compared alirocumab with 
usual care [ezetimibe, fenofibrate, omega-3, niacin, and 
no additional lipid-lowering therapy (LLT)] in adults with 
T2DM and mixed dyslipidemia (non‐HDL-C ≥ 100 mg/
dL and TGs ≥ 150 and < 500  mg/dL) receiving stable 
maximally tolerated statin dose (n = 413) [13]. The trial 
showed that the primary endpoint of reduction in non-
HDL-C with alirocumab was superior to usual care over-
all (mean difference of − 32.5% vs usual care at Week 24; 
P < 0.0001) and versus fenofibrate (mean difference of 
− 33.3% vs fenofibrate at Week 24; P < 0.0001), and that 
alirocumab was generally well tolerated [14].
The aim of this post hoc analysis of the DM-DYSLIPI-
DEMIA study was to focus on a higher risk and more dif-
ficult to treat subpopulation compared with the primary 
trial population, and provide analyses of other lipids 
beyond the primary endpoint.
Methods
Primary analysis
Detailed methods of the DM-DYSLIPIDEMIA study 
have been reported previously [13]. Briefly, individu-
als were randomized 2:1 to receive alirocumab or usual 
care for 24  weeks. All individuals were receiving maxi-
mally tolerated statin. Usual care included addition of 
ezetimibe, fenofibrate, no additional LLT, omega-3 fatty 
acid, or nicotinic acid. Randomization was stratified by 
the investigator’s choice of usual care therapy, which was 
prespecified prior to randomization.
The primary analysis included adults with T2DM 
and mixed dyslipidemia (non‐HDL-C ≥ 100 mg/dL; 
TGs ≥ 150 and < 500  mg/dL) receiving stable maximally 
tolerated statin dose for at least 4 weeks prior to screen-
ing, without other LLT, and who had a documented his-
tory of ASCVD or at least one additional cardiovascular 
risk factor, and glycated hemoglobin (HbA1c) < 9.0%. The 
maximally tolerated dose of statin was based on inves-
tigator judgement. Individuals with documented statin 
intolerance and therefore not receiving statin therapy 
could also be enrolled.
Post hoc subgroup analysis
In this post hoc subgroup analysis, the effect of ali-
rocumab versus usual care on non-HDL-C and other 
lipids was investigated in a subgroup of individuals 
with alirocumab than ezetimibe, fenofibrate, or no LLT. Consistent with previous studies, alirocumab was generally 
well tolerated.
Trial registration Clinicaltrials.gov, NCT02642159. Registered December 24, 2015, https ://clini caltr ials.gov/ct2/show/
NCT02 64215 9
Keywords: Alirocumab, PCSK9, Diabetes mellitus, Non‑HDL‑C, HDL‑C, Triglycerides, ODYSSEY, DM‑DYSLIPIDEMIA, 
Type 2 diabetes, Usual care
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with baseline levels of non-HDL-C ≥ 100  mg/dL, 
TGs ≥ 200  mg/dL, and HDL-C < 40  mg/dL (men) 
or < 50  mg/dL (women). The thresholds for TGs and 
HDL-C in this analysis reflect those used in previ-
ous analyses of the effects of fenofibrate on cardio-
vascular events in the ACCORD (TGs ≥ 204  mg/
dL, HDL-C ≤ 34  mg/dL) [15] and FIELD trials 
[TGs ≥ 150.6  mg/dL, HDL-C ≤ 39.8  mg/dL (men) 
or ≤ 49.9  mg/dL (women)] [16], and icosapent-ethyl 
in the amended REDUCE-IT trial protocol [TGs 200–
499 mg/dL and HDL-C ≤ 40 mg/dL (men) or ≤ 50 mg/
dL (women)] [17].
This analysis provides an overall comparison of ali-
rocumab versus usual care (ezetimibe, fenofibrate, no 
additional LLT, omega-3 fatty acid, and nicotinic acid), 
and separate analyses of alirocumab versus ezetimibe, 
fenofibrate, and no LLT. Due to low participant numbers, 
nicotinic acid and omega-3 fatty acid strata were not 
compared separately to alirocumab.
Endpoint
The primary efficacy endpoint of the DM-DYSLIPI-
DEMIA study was the percentage change in non-HDL-
C from baseline to Week 24. In this analysis, percentage 
change from baseline in LDL-C (measured by beta-quan-
tification), non-HDL-C, ApoB, LDL particle number, 
Lp(a), TGs, TRL-C (i.e. non-HDL-C minus LDL-C), and 
HDL-C with alirocumab and usual care at Week 24 was 
analyzed in the intention-to-treat population); addition-
ally, estimates for alirocumab versus ezetimibe, fenofi-
brate, and no LLT differences were derived from the 
same model with appropriate contrasts.
Statistical analyses
For LDL-C, non-HDL-C, ApoB, LDL particle number, 
and HDL-C, least squares (LS) mean difference [stand-
ard error (SE)] with alirocumab versus usual care was 
analyzed by a mixed-effect model with repeat measure-
ments to manage missing data. For Lp(a) and TGs, which 
are not normally distributed, a combined estimate for 
adjusted mean difference (SE) with alirocumab versus 
usual care was calculated by using multiple imputation 
to manage missing data, followed by robust regression. 
The combined estimates for proportions (%) of indi-
viduals reaching ApoB < 80 mg/dL at Week 24 and non-
HDL-C < 100 mg/dL at Week 24 were obtained by using 
multiple imputation to manage missing data, followed 
by logistic regression. The safety analysis was descrip-
tive and based on the safety population and was analyzed 
according to the treatment group (alirocumab or usual 
care).
Results
Of the 413 individuals included in the primary 
DM-DYSLIPIDEMIA study, this post hoc analysis 
included 186 individuals with TGs ≥ 200  mg/dL and 
HDL-C < 40 mg/dL (men) or < 50 mg/dL (women), ran-
domized to alirocumab (n = 128) or usual care (n = 58). 
Figure 1 provides the patient flow chart for the ODYS-
SEY DM-DYSLIPIDEMIA post hoc analysis, showing 
the number of individuals randomized to each usual 
care stratum. Separate analyses were conducted for ali-
rocumab versus ezetimibe (n = 16), fenofibrate (n = 15), 
and no LLT (n = 20). Due to low participant numbers, 
nicotinic acid (n = 1) and omega-3 fatty acid (n = 6) 
strata were not compared separately to alirocumab.
Baseline characteristics were generally similar across 
treatment groups (Table 1). Similar proportions of indi-
viduals in the alirocumab and usual care groups had 
ASCVD (defined as coronary heart disease, peripheral 
arterial disease, or ischemic stroke; 36.7% vs 41.4%) 
and were receiving insulin (40.6% vs 44.8%) at base-
line. Mean (standard deviation [SD]) HbA1c at baseline 
was also similar between groups [7.0% (0.9) in the ali-
rocumab group and 7.3% (0.8) in the usual care group].
Overall, alirocumab significantly reduced non-
HDL-C [LS mean difference (SE): − 35.0% (3.9)] and 
ApoB [LS mean difference (SE): − 34.7% (3.6)], as 
well as LDL-C [LS mean difference (SE): − 47.3% 
(5.2)], LDL particle number [LS mean difference (SE) 
− 40.8% (4.1)], and Lp(a) [adjusted mean (SE]) − 29.9% 
(5.4)] from baseline to Week 24 versus usual care (all 
P < 0.0001; Fig. 2a). In addition, all comparisons for per-
centage change from baseline in non-HDL-C, ApoB, 
LDL-C, LDL particle number, and Lp(a) with ali-
rocumab versus ezetimibe, fenofibrate, or no additional 
LLT were significant (P < 0.01; Fig. 2b–d, respectively).
Alirocumab reduced TGs to a greater extent than 
usual care overall, ezetimibe, or no LLT [adjusted mean 
difference (SE): − 5.0% (5.2) vs usual care; − 18.2% (9.7) 
vs ezetimibe; − 13.5% (9.7) vs no LLT]; however, mean 
TG reductions were greater with fenofibrate than ali-
rocumab [adjusted mean difference (SE): 9.6% (10.0)]. 
P-values were not significant for any comparison 
(Fig. 2).
Overall, alirocumab significantly increased HDL-C 
compared with usual care [LS mean difference (SE): 7.9% 
(3.6); P < 0.05] and no LLT strata [LS mean difference 
(SE): 16.0% (6.5); P < 0.05]; however, LS mean difference 
(SE) with alirocumab versus ezetimibe or alirocumab 
versus fenofibrate was non-significant [11.6% (6.5) vs 
ezetimibe; − 5.2% (6.9) vs fenofibrate; Fig.  2]. The LS 
mean difference (SE) in TRL-C was significantly reduced 
with alirocumab versus usual care overall [− 9.9% 
(4.8); P = 0.0402; Fig.  2a]. However, P-values were not 
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significant for alirocumab versus ezetimibe, fenofibrate, 
or no additional LLT (Fig. 2b–d).
ApoB < 80  mg/dL was achieved by 67.9% of ali-
rocumab-treated individuals compared with 41.5% of 
individuals in the usual care group (Fig. 3). Similar trends 
were observed by strata (alirocumab vs ezetimibe: 76.9% 
vs 44.5%; alirocumab vs fenofibrate: 67.8% vs 55.6%; ali-
rocumab vs no additional LLT: 60.8 vs 26.7%). In addi-
tion, non-HDL-C < 100 mg/dL was achieved in 60.9% of 
alirocumab-treated individuals compared with 32.0% 
of individuals in the usual care group. Likewise, similar 
trends were observed by strata (alirocumab vs ezetimibe: 
69.2% vs 29.2%; alirocumab vs fenofibrate: 57.5% vs 
44.4%; alirocumab vs no additional LLT: 53.8% and 
26.7%).
The frequency of treatment-emergent adverse events 
(TEAEs) was similar in the alirocumab and usual care 
groups (67.2% vs 70.7%, respectively; Table  2). Treat-
ment-emergent serious adverse events occurred in 6.3% 
and 5.2% of individuals receiving alirocumab and usual 
care, respectively. No deaths occurred in either treat-
ment group. Discontinuations due to adverse events were 
similar in the alirocumab and usual care groups (3.1% vs 
3.4%, respectively; Table  2). TEAEs occurring in ≥ 2% 
of individuals are also shown in Table 2. The most com-
mon TEAEs in the alirocumab group were urinary tract 
infection (8.6%), viral upper respiratory tract infection 
(5.5%), and influenza and diarrhea (both 4.7%). The most 
common TEAEs in the usual care group were bronchitis 
(8.6%), diarrhea (6.9%), and arthralgia (6.9%).
Mean (SD) change from baseline at Week 24 in fasting 
plasma glucose was + 11.3 (51.5) mg/dL and + 2.9 (50.3) 
mg/dL, and in HbA1c was + 0.3 (0.7)% and + 0.3 (0.7)%, 
in the alirocumab and usual care groups, respectively. 
The number of antihyperglycemic agents being used was 
similar at baseline and Week 24 in both the alirocumab 
group [1.9 (1.0) and 2.0 (1.0), respectively] and the usual 
care group [2.0 (1.0) and 2.1 (1.0), respectively].
Discussion
Individuals with T2DM are at increased risk of ASCVD 
[1], and mixed dyslipidemia further increases this risk [3, 
18]. A recent analysis of 9593 statin-treated adults in the 
US National Health and Nutrition Examination Surveys 
found that the prevalence of TGs < 150, 150–199, and 
≥ 200  mg/dL was 68.4%, 16.2%, and 15.4%, respectively 
Fig. 1 Patient flow chart for the ODYSSEY DM‑DYSLIPIDEMIA post hoc analysis. ALI, alirocumab; ASCVD, atherosclerotic cardiovascular disease; CV, 
cardiovascular; HDL‑C, non‑high‑density lipoprotein cholesterol; LLT, lipid‑lowering therapy; TG, triglyceride; T2DM, type 2 diabetes mellitus
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Table 1 Baseline demographics (ITT population)
ASCVD atherosclerotic cardiovascular disease, ApoB apolipoprotein B, BMI body mass index, CHD coronary heart disease, HbA1c glycated hemoglobin, HDL-C high-
density lipoprotein cholesterol, ITT intention-to-treat, LDL low-density lipoprotein, LDL-C low-density lipoprotein cholesterol, PAD peripheral artery disease, SD 
standard deviation, TG triglyceride
a Options included ezetimibe, fenofibrate, no additional lipid-lowering therapy, omega-3 fatty acid, and nicotinic acid
Alirocumab (n = 128) Usual  carea (n = 58)
Age, years, mean (SD) 62.1 (9.5) 63.4 (9.0)
Male, n (%) 65 (50.8) 28 (48.3)
Race, n (%)
 American Indian or Alaska Native 3 (2.3) 0
 Asian/Oriental 2 (1.6) 6 (10.3)
 Black 4 (3.1) 2 (3.4)
 Other 3 (2.3) 0
 White/Caucasian 116 (90.6) 50 (86.2)
Ethnicity, n (%)
 Hispanic or Latino 17 (13.3) 8 (13.8)
 Not Hispanic or Latino 110 (85.9) 50 (86.2)
 Not reported/unknown 1 (0.8) 0
Weight, kg, mean (SD) 93.6 (19.7) 93.8 (16.4)
BMI, kg/m2, mean (SD) 32.6 (4.9) 33.0 (4.6)
Systolic blood pressure, mmHg, mean (SD) 130.0 (14.4) 134.9 (15.7)
Diastolic blood pressure, mmHg, mean (SD) 76.3 (9.8) 77.2 (9.2)
ASCVD (CHD, ischemic stroke, PAD), n (%) 47 (36.7) 24 (41.4)
HbA1c, %, mean (SD) 7.0 (0.9) 7.3 (0.8)
Fasting plasma glucose, mg/dL, mean (SD) 150.2 (39.2) 153.2 (41.1)
Individuals receiving insulin at baseline, n (%) 52 (40.6) 26 (44.8)
Baseline lipids, mean (SD)
 Non‑HDL‑C, mg/dL 170.3 (48.2) 166.3 (48.8)
  mmol/L 4.41 (1.25) 4.31 (1.26)
 LDL‑C (beta‑quantification), mg/dL 112.8 (43.7) 110.7 (42.1)
  mmol/L 2.92 (1.13) 2.87 (1.09)
 ApoB, mg/dL 109.3 (27.4) 108.1 (28.9)
 LDL particle number, nmol/L 1497.3 (532.0) 1491.5 (545.1)
 Lipoprotein(a), mg/dL, median (Q1:Q3) 18.0 (5.0:55.0) 9.5 (4.0:30.0)
 TGs, mg/dL, median (Q1:Q3) 281.5 (245.0:369.0) 269.0 (232.0:328.0)
  mmol/L 3.19 (2.77:4.17) 3.04 (2.62:3.71)
 HDL‑C, mg/dL 34.4 (6.2) 34.3 (5.9)
  mmol/L 0.89 (0.16) 0.89 (0.15)
(See figure on next page.)
Fig. 2 Percent change from baseline in LDL‑C, non‑HDL‑C, ApoB, LDL particle number, Lp(a), TGs, HDL‑C, and TRL‑C at Week 24 with alirocumab 
versus usual care (panel a), ezetimibe (panel b), fenofibrate (panel c), and no LLT (panel d) (ITT population). ApoB, apolipoprotein B; HDL‑C, 
high‑density lipoprotein cholesterol; ITT, intention‑to‑treat; LDL, low‑density lipoprotein; LDL‑C, low‑density lipoprotein cholesterol; LLT, 
lipid‑lowering therapy; Lp(a), lipoprotein(a); SE, standard error; TG, triglyceride; TRL‑C, triglyceride‑rich lipoprotein cholesterol. Usual care options 
were selected by the investigator prior to stratified randomization to alirocumab or usual care. Usual care options included ezetimibe, fenofibrate, 
no additional LLT, omega‑3 fatty acid, and nicotinic acid; due to low participant numbers, nicotinic acid and omega‑3 fatty acid strata are not 
analyzed separately here. a No additional LLT on top of background maximally tolerated statin dose
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[19]. In those on statin therapy with TGs ≥ 200 mg/dL, 
approximately half a million ASCVD events were esti-
mated to occur in the next 10  years, with an estimated 
10-year ASCVD risk score of 14.4%, compared to 11.3% 
for those with TGs < 150 mg/dL [19]. Furthermore, indi-
viduals with low HDL-C levels, despite receiving statin 
therapy, have been shown to have higher residual cardio-
vascular risk [20, 21]. There is therefore an opportunity 
for cardiovascular outcomes to be improved in individu-
als with T2DM and dyslipidemia who are receiving statin 
therapy.
Current approaches to reducing cardiovascular risk are 
tackling production of TG or ApoB particles [22, 23]. An 
alternative way to reduce residual risk is to reduce ath-
erogenic lipoproteins. We tested this hypothesis in this 
subgroup of individuals with T2DM, elevated TGs, and 
low HDL-C. In these individuals, alirocumab significantly 
reduced LDL-C, non-HDL-C, ApoB, Lp(a), and LDL par-
ticle number compared with usual care. These results 
were comparable with the primary trial [14]; however, 
this analysis provides insight to the effects of alirocumab 
in the subgroup of individuals with high TG and low 
HDL-C despite statins, and who have higher residual car-
diovascular risk than those without dyslipidemia. Most 
individuals receiving alirocumab achieved ApoB < 80 mg/
dL and non-HDL-C < 100  mg/dL (67.9% and 60.9%, 
respectively). As these lipid parameters are associated 
with increased cardiovascular risk [2], the improvements 
observed with alirocumab may result in decreased car-
diovascular risk. Similar findings have been obtained 
with evolocumab: the BANTING trial (NCT02739984) 
demonstrated that evolocumab significantly reduced 
LDL-C and non-HDL-C compared with placebo in adults 
with T2DM and hypercholesterolemia/dyslipidemia on 
a maximally tolerated oral dose of statin over 12  weeks 
[24].
Consistent with previous findings in participants with 
T2DM [14, 25], alirocumab resulted in non-significant 
TG reductions. These data confirm that blocking extra-
cellular PCSK9 pathways with PCSK9 monoclonal anti-
bodies does not affect hepatic ApoB production, and that 
the modest reduction in TGs is likely due to an increased 
uptake/catabolism of large very-low-density lipopro-
tein particles through the LDL receptor [26]. In previous 
studies with gemfibrozil in the Helsinki Heart Study [27] 
and fenofibrate in the ACCORD trial [15], TG lowering 
was generally not associated with overall cardiovascular 
benefit, but improvements were observed in subgroups 
with high TGs and low HDL-C (Helsinki Heart Study: 
TGs > 200  mg/dL, LDL-C/HDL-C ratio > 5.0; ACCORD: 
TGs ≥ 204 mg/dL, HDL-C ≤ 34 mg/dL).
This post hoc analysis provides useful data for com-
parison with several recently completed or ongoing car-
diovascular outcome trials with similar thresholds for 
TGs and HDL-C. The REDUCE-IT trial demonstrated a 
reduction in cardiovascular events with 4 g of icosapent 
ethyl versus placebo (hazard ratio, 0.75; 95% confidence 
interval, 0.68–0.83; P < 0.001) over a median follow up of 
4.9 years [17, 28]. In the ASCEND trial (NCT00135226), 
1  g of eicosapentaenoic acid once daily did not reduce 
the risk of cardiovascular events versus placebo [29]. 
Other trials are currently ongoing with 4  g of omega-3 
Fig. 3 Proportion of individuals achieving ApoB < 80 mg/dL and non‑HDL‑C < 100 mg/dL for alirocumab versus usual care, alirocumab versus 
ezetimibe, alirocumab versus fenofibrate, and alirocumab versus no LLT (ITT population). ApoB, apolipoprotein B; HDL‑C, high‑density lipoprotein 
cholesterol; ITT, intention‑to‑treat; LLT, lipid‑lowering therapy. a Usual care options included continuing on maximally tolerated dose of statins (or no 
statin if intolerant) with no additional LLT, or with the addition of ezetimibe, fenofibrate, omega‑3 fatty acids, or nicotinic acid
Page 8 of 11Colhoun et al. Cardiovasc Diabetol           (2020) 19:14 
carboxylic acids (STRENGTH, NCT02104817) and 
pemafibrate (PROMINENT, NCT03071692).
Consistent with previous studies, alirocumab was well 
tolerated in individuals with T2DM [14, 25, 30, 31]. In 
addition, no clinically relevant effect of alirocumab on 
change in glycemic parameters or in use of antihyper-
glycemic agents was observed, in accordance with pre-
vious data [32]. A recent study in patients with stable 
CAD demonstrated that low PCSK9 plasma levels are 
associated with low HDL-C, metabolic syndrome, obe-
sity, insulin resistance, and diabetes, and diffuse non-
obstructive coronary atherosclerosis [33]. However, 
studies to date have not shown an association between 
PCSK9 inhibitors and low HDL-C or increased risk of 
diabetes, metabolic syndrome, or obesity [34–36]. Fur-
thermore, similar safety findings were observed with 
alirocumab across BMI subgroups, with no difference 
in percentage change from baseline in body weight 
Table 2 Overview of TEAEs (safety population)
SAE serious adverse event, TEAE treatment-emergent adverse event
a Options included ezetimibe, fenofibrate, no additional lipid-lowering therapy, omega-3 fatty acid, and nicotinic acid
b Given in alphabetical order
n (%) Alirocumab (n = 128) Usual  carea (n = 58)
Any TEAE 86 (67.2) 41 (70.7)
Any treatment‑emergent SAE 8 (6.3) 3 (5.2)
Any TEAE leading to death 0 0
Any TEAE leading to permanent treatment discontinuation 4 (3.1) 2 (3.4)
TEAEs occurring in ≥ 2% of individuals (preferred level term)b
 Anemia 3 (2.3) 0
 Arthralgia 2 (1.6) 4 (6.9)
 Back pain 1 (0.8) 2 (3.4)
 Bronchitis 1 (0.8) 5 (8.6)
 Cellulitis 3 (2.3) 0
 Cough 1 (0.8) 3 (5.2)
 Diarrhea 6 (4.7) 4 (6.9)
 Dizziness 2 (1.6) 2 (3.4)
 Dyspnea 1 (0.8) 2 (3.4)
 Fall 3 (2.3) 2 (3.4)
 Fatigue 5 (3.9) 1 (1.7)
 Headache 2 (1.6) 3 (5.2)
 Hyperinsulinemic hypoglycemia 3 (2.3) 0
 Hypoglycemia 2 (1.6) 2 (3.4)
 Hypotension 1 (0.8) 2 (3.4)
 Influenza 6 (4.7) 2 (3.4)
 Injection‑site bruising 3 (2.3) 0
 Injection‑site pruritus 4 (3.1) 0
 Injection‑site reaction 5 (3.9) 0
 Muscle spasms 3 (2.3) 1 (1.7)
 Musculoskeletal pain 4 (3.1) 2 (3.4)
 Myalgia 3 (2.3) 1 (1.7)
 Nausea 4 (3.1) 2 (3.4)
 Osteoarthritis 0 2 (3.4)
 Pain in extremity 1 (0.8) 2 (3.4)
 Sinusitis 1 (0.8) 2 (3.4)
 Type 2 diabetes mellitus 1 (0.8) 2 (3.4)
 Upper respiratory tract infection 5 (3.9) 2 (3.4)
 Urinary tract infection 11 (8.6) 2 (3.4)
 Viral upper respiratory tract infection 7 (5.5) 1 (1.7)
 Vitamin D deficiency 0 2 (3.4)
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observed between alirocumab and control at Weeks 12, 
24, and 52 [34]. However, studies of longer duration are 
required to further assess these potential effects.
This subgroup analysis was limited by the post-rand-
omization nature of post hoc analyses, the relatively low 
number of participants, and the short duration of the 
study (24  weeks). In addition, comparisons were made 
with no adjustment on the type I error rate. Although 
DM-DYSLIPIDEMIA was not designed to assess car-
diovascular outcomes, these findings are supported by 
the results of the ODYSSEY OUTCOMES cardiovas-
cular outcomes trial [37]. A prespecified analysis of the 
ODYSSEY OUTCOMES trial showed that alirocumab 
treatment targeting LDL-C 25–50  mg/dL produced 
approximately twice the absolute reduction in cardio-
vascular events in individuals with diabetes as in those 
without diabetes. In addition, alirocumab treatment did 
not increase the risk of new-onset diabetes [31]. Since the 
objective of this post hoc analysis was to analyze a sub-
group of patients with TGs > 200 mg/dL and low HDL-C, 
no analysis by stratification by baseline TG levels were 
conducted; however, in the primary paper, reduction 
in non-HDL-C was similar at TG thresholds of < 150, 
150–< 200, and ≥ 200 mg/dL [14].
Conclusions
In individuals with T2DM and mixed dyslipidemia, ali-
rocumab significantly reduced LDL-C, non-HDL-C, 
ApoB, Lp(a), and LDL particle number, and significantly 
increased HDL-C, compared with usual care overall. 
Reduction with alirocumab in atherogenic lipids (ApoB 
and non-HDL) was greater than with ezetimibe, fenofi-
brate, or no additional LLT. In addition, alirocumab was 
effective for achieving target non-HDL-C and ApoB, 
compared with usual care, in this high cardiovascular risk 
subgroup population. Consistent with previous studies, 
alirocumab was generally well tolerated.
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